$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000117891314001274 Filed on April 10, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$810.0K	$510.0K	$510.0K
YoY Change	62.0%	0.0%	121.74%
% of Gross Profit
Research & Development	$1.089M	$674.0K	$749.0K
YoY Change	30.36%	-10.01%	5.4%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.089M	$674.0K	$749.0K
YoY Change	30.36%	-10.01%	5.4%
Operating Profit	-$1.903M	-$1.186M	-$1.260M
YoY Change	42.6%	-5.86%	33.97%
Interest Expense	$80.00K	$70.00K	$30.00K
YoY Change	0.0%	133.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.830M	-$1.115M	-$1.226M
YoY Change	45.66%	-9.06%	24.41%
Income Tax
% Of Pretax Income
Net Earnings	-$1.828M	-$1.115M	-$1.226M
YoY Change	45.49%	-9.04%	24.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$185.0K	-$121.6K	-$170.6K
COMMON SHARES
Basic Shares Outstanding	9.943M shares	9.745M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.54M	$23.35M	$5.340M
YoY Change	267.38%	337.27%	78.0%
Cash & Equivalents	$2.475M	$3.253M	$2.040M
Short-Term Investments	$13.07M	$20.10M	$3.300M
Other Short-Term Assets	$160.0K	$270.0K	$60.00K
YoY Change	100.0%	350.0%	100.0%
Inventory
Prepaid Expenses			$36.41K
Receivables			$439.8K
Other Receivables	$267.1K	$73.05K	$99.53K
Total Short-Term Assets	$15.97M	$23.69M	$5.939M
YoY Change	231.06%	298.81%	91.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.55K	$12.16K	$1.869K
YoY Change	136.42%	550.83%	-76.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.510M	$0.00	$10.00K
YoY Change	65000.0%	-100.0%	0.0%
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	-50.0%
Total Long-Term Assets	$6.529M	$23.06K	$17.93K
YoY Change	28893.67%	28.61%	-47.73%
TOTAL ASSETS
Total Short-Term Assets	$15.97M	$23.69M	$5.939M
Total Long-Term Assets	$6.529M	$23.06K	$17.93K
Total Assets	$22.50M	$23.71M	$5.957M
YoY Change	364.23%	298.0%	89.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$450.0K	$300.0K	$420.0K
YoY Change	12.5%	-28.57%	-20.75%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$495.0K	$349.8K	$469.4K
YoY Change	10.99%	-25.47%	-19.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K	$30.00K	$240.0K
YoY Change	-87.5%	-87.5%	50.0%
Total Long-Term Liabilities	$31.94K	$32.42K	$239.9K
YoY Change	-86.75%	-86.49%	48.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$495.0K	$349.8K	$469.4K
Total Long-Term Liabilities	$31.94K	$32.42K	$239.9K
Total Liabilities	$527.0K	$382.2K	$709.3K
YoY Change	-23.3%	-46.11%	-4.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.19M	-$24.36M	-$20.08M
YoY Change	22.77%	21.35%	25.39%
Common Stock	$47.69M	$46.84M	$25.08M
YoY Change	88.07%	86.78%	36.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.97M	$23.33M	$5.248M
YoY Change
Total Liabilities & Shareholders Equity	$22.50M	$23.71M	$5.957M
YoY Change	364.23%	298.0%	89.57%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$1.828M	-$1.115M	-$1.226M
YoY Change	45.49%	-9.04%	24.41%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$1.040M	-$1.480M	-$1.280M
YoY Change	-0.95%	15.63%	113.33%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$110.0K	-$13.12M	-$2.200M
YoY Change	0.0%	496.36%	-329.17%
Cash From Investing Activities	$110.0K	-$13.13M	-$2.200M
YoY Change	0.0%	496.82%	-329.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	150.0K	16.49M	-10.00K
YoY Change		-165000.0%
NET CHANGE
Cash From Operating Activities	-1.040M	-1.480M	-1.280M
Cash From Investing Activities	110.0K	-13.13M	-2.200M
Cash From Financing Activities	150.0K	16.49M	-10.00K
Net Change In Cash	-780.0K	1.880M	-3.490M
YoY Change	-17.02%	-153.87%	-1069.44%
FREE CASH FLOW
Cash From Operating Activities	-$1.040M	-$1.480M	-$1.280M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$1.040M	-$1.470M	-$1.280M
YoY Change	-0.95%	14.84%	113.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	8437	USD
CY2008	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2009	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2010	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3780	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
CY2013Q1	ormp	Common Stock Shares Authorized Prior To Reverse Stock Split CommonStockSharesAuthorizedPriorToReverseStockSplit	200000000	shares
CY2013Q1	ormp	Common Stock Shares Issued Prior To Reverse Stock Split CommonStockSharesIssuedPriorToReverseStockSplit	86500000	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-02-28
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9942589	shares
CY2013Q1	ormp	Common Stock Shares Outstanding Prior To Reverse Stock Split CommonStockSharesOutstandingPriorToReverseStockSplit	86500000	shares
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
CY2011	ormp	Finders Fee Shares FindersFeeShares	13872	shares
CY2011Q3	ormp	Marketable Securities Number MarketableSecuritiesNumber	8404667	shares
CY2014Q1	ormp	Marketable Securities Ownership Percentage MarketableSecuritiesOwnershipPercentage	0.103	pure
	ormp	Marketable Securities Sold MarketableSecuritiesSold	1625989	shares
CY2011	ormp	Note Receivable Interest Rate NoteReceivableInterestRate	0.0045	pure
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised		USD
	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	1489770	USD
	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	1599345	USD
CY2008	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
CY2014Q1	ormp	Royalty Receivable Percentage RoyaltyReceivablePercentage	0.03	pure
CY2013	ormp	Stock Issued During Period Value Marketable Securities StockIssuedDuringPeriodValueMarketableSecurities	628630	USD
	ormp	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts		USD
CY2009	ormp	Stock Issued During Period Value Services To Be Rendered StockIssuedDuringPeriodValueServicesToBeRendered	203699	USD
CY2012	ormp	Stock Issued During Period Value Shares To Be Issued StockIssuedDuringPeriodValueSharesToBeIssued	25093	USD
	ormp	Stock Issued During Period Value Shares To Be Issued StockIssuedDuringPeriodValueSharesToBeIssued	118128	USD
CY2013	ormp	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	109575	USD
	ormp	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	1489770	USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
	ormp	Warrants Exchanged WarrantsExchanged		USD
	ormp	Warrants Exchanged WarrantsExchanged	296982	USD
	ormp	Warrants Exercised WarrantsExercised	258849	shares
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	450941	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	302567	USD
CY2013Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2014Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-23559	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	303403	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	846985	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29855723	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	46726183	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	177782	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	203982	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	117174	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	116944	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	26733	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	70292	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	156253	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	57016	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1968547	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	459467	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	436025	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	690882	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	200866	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	562966	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	276121	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	917809	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2013Q3	us-gaap	Assets Assets	8660182	USD
CY2014Q1	us-gaap	Assets Assets	23709956	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	8644276	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	23686895	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2272228	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4430740	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3252911	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2039905	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2390835	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	980683	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3252911	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16666667	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7937872	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9776167	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7200000	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7937872	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9776167	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7200000	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	95238	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	117298	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-602030	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1940119	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1695580	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1217234	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2184627	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2239162	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1225874	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-25039	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	33426	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23515766	USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2011Q3	us-gaap	Cost Method Investments CostMethodInvestments	1027	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	917809	USD
CY2013Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5246627	USD
CY2014Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	18633526	USD
	us-gaap	Depreciation Depreciation	2899	USD
	us-gaap	Depreciation Depreciation	2983	USD
	us-gaap	Depreciation Depreciation	129206	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	44699	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-98005	USD
CY2013Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	4530	USD
CY2014Q1	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1712	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-26163	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	9982	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-18229	USD
	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	10.00
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-16790	USD
CY2014Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2013Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	28034	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	44391	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1128098	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	512252	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	850047	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	929979	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	510834	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11123655	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1114842	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24327037	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35714	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-175031	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-148374	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	302567	USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes		USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes		USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	23210	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	4667	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	1208	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	22439	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	403870	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167313	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	330566	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	2615	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2013Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	4593	USD
CY2014Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	4593	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	64400	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1464813	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5715	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	9603	USD
CY2012	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P57M
	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P36M
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8660182	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23709956	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	498193	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	349819	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	31214	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	32422	USD
CY2013Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	23210	USD
CY2014Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	23210	USD
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	956376	USD
CY2014Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1464100	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> <!--StartFragment--> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> General:</div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 72.85pt"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">  </div> </td> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 1)</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> Incorporation and operations</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011. See also note 2a.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary").</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr valign="top"> <td style="WIDTH: 72.85pt"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">  </div> </td> <td style="WIDTH: 27pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 2)</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: left"> Development and liquidity risks</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.<font style="FONT-WEIGHT: bold; DISPLAY: inline"> </font> Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with ASC Topic 915 "Development Stage Entities", due to the fact that it has not generated any revenues from its operations.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt">  </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 99pt; MARGIN-RIGHT: -0.05pt; text-align: left; TEXT-INDENT: 0pt"> Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.</div> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1450936	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16494983	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37811415	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1750018	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13293344	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18028616	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2065590	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2230938	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16511659	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4478917	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-2769271	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-2760474	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2977376	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3344478	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4231812	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1114842	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2184627	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2239162	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-1225874	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24362751	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1185586	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1991669	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2353823	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1259830	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24786863	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	89052	ILS
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	25422	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	89052	ILS
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	25422	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	89052	ILS
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	25422	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	48498	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	122977	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	53820	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5630	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	184665	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-16	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	303403	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	512812	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	244508	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	543582	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8640	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	846985	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	25937	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50687	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	44391	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50687	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	134761	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	490251	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	172218	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	534153	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	53697	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	797081	USD
CY2014Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3213	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	332002	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	5419	USD
CY2013Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	32844	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	699245	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	73957	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	139044	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	120080	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	66800	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	507733	USD
CY2013Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	58412	USD
CY2014Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	73050	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1		USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	628630	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	9485	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	815500	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90103	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	245596	USD
CY2013Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	5545	USD
CY2014Q1	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	6304	USD
CY2014Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2013Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
CY2014Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2013Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	381666	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1331	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	500	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9379	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141370	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1862817	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18600000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	30350363	USD
CY2013Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	8004	USD
CY2014Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	9212	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14887085	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1450936	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	14887085	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35746638	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	118128	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	118128	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80249	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5236286	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	11718297	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	114130	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	80249	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	756920	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54804	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1553094	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5768	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12164	USD
CY2011Q3	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	450000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	673334	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1141622	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1423844	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	748996	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13228332	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22123589	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24362751	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	441084	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	333137	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6023643	USD
	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	10000	shares
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	8130775	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	3778013	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	2746192	USD
CY2008Q3	us-gaap	Stockholders Equity StockholdersEquity	4593060	USD
CY2007Q3	us-gaap	Stockholders Equity StockholdersEquity	513131	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	23327715	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2014Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	19688	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9134	shares
CY2008	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	98750	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	4238889	USD
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	14887085	USD
CY2008	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	116110	USD
	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	1580000	shares
CY2009	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	152928	USD
CY2010	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	249850	USD
CY2011	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	227569	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	107860	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	244457	USD
CY2013	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	12	pure
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	77779	USD
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	239161	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	64400	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2122981	USD
CY2008	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5784800	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2944464	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1422592	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue		USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9127799	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7018766	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8531150	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7212767	shares

Files In Submission

Name	View Source	Status
0001178913-14-001274-index-headers.html	Edgar Link	pending
0001178913-14-001274-index.html	Edgar Link	pending
0001178913-14-001274.txt	Edgar Link	pending
0001178913-14-001274-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ormp-20140228.xml	Edgar Link	completed
ormp-20140228.xsd	Edgar Link	pending
ormp-20140228_cal.xml	Edgar Link	unprocessable
ormp-20140228_def.xml	Edgar Link	unprocessable
ormp-20140228_lab.xml	Edgar Link	unprocessable
ormp-20140228_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1414728.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2014 Q2 Form 10-Q Financial Statement

#000117891314001274 Filed on April 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2014 Q2 Form 10-Q Financial Statement

#000117891314001274 Filed on April 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp